Garda Therapeutics

Garda Therapeutics is a pre-clinical stage biotechnology company dedicated to developing novel treatments for neurodegenerative disorders, specifically Alzheimer's disease. The company was founded as a spin-off from the University of Minnesota's Center for Drug Design to commercialize research focused on oxidative stress and neuroinflammation. Its lead candidate, GT-001, is a small molecule prodrug designed to cross the blood-brain barrier and replenish brain glutathione levels. By restoring this critical antioxidant, Garda Therapeutics aims to protect neurons from damage and slow the progression of cognitive decline. The company's approach represents a targeted strategy to address the metabolic and inflammatory components of dementia.